Neuroimaging Studies of Depression in Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

Neuroimaging Studies of Depression in Parkinson's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00518258
• Other study ID #: R01-MH78228-2
• Status: Completed
• Phase: N/A
• First received: August 16, 2007
• Last updated: May 16, 2013
• Start date: July 2006
• Est. completion date: December 2011

Study information

• Verified date: April 2013
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate similarities and differences in the neural pathways of depressed Parkinson's patients, non-depressed Parkinson's patients, and healthy controls using magnetic resonance imaging (MRI) of the brain and neuropsychological assessment.

Description:

Depression is a common and potentially serious complication of Parkinson's disease (PD). Studies show that approximately 40 percent of PD patients are depressed. There is evidence that these patients have deficits in neuropsychological function relative to non-depressed PD patients. Despite the widespread toll on emotional health posed by PD, few studies have undertaken a comprehensive examination of the neural underpinnings of Parkinsonian depression. In this project, we will compare depressed versus non-depressed Parkinson patients to a sample of demographically-matched healthy controls using neuropsychological assessment and magnetic resonance imaging (MRI). To investigate possible effects of anti-Parkinsonian medication on mood, cognitive function, and neural response, PD patients will be tested both off and on Parkinsonian medications.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• right-handed

• willing/able to undergo magnetic resonance imaging (MRI)

Exclusion Criteria:

• history of neurological condition other than Parkinson's disease

• history of psychiatric condition other than depression

• history of substance abuse/dependence

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Locations

Country	Name	City	State
United States	University of Kentucky	Lexington	Kentucky

Sponsors (3)

Lead Sponsor	Collaborator
Lee Blonder	National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States,